Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04113837
Other study ID # H9_19
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 29, 2019
Est. completion date March 23, 2020

Study information

Verified date September 2019
Source University of Jena
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed intervention study is designed to evaluate the physiological impact of the regular consumption of the developed foods with improved nutrient profile (verum) in comparison to commercial available foods (control) by a controlled, randomized, double-blind crossover study with patients with measurable cardiovascular risk factors (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / Triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)).


Description:

The proposed intervention study is designed to evaluate the physiological impact of regularly consumption of the food range with improved nutrient profile (verum) in comparison to commercially available foods (control/placebo).

The controlled, randomized, double-blind crossover study consists of 4-week investigation periods with a 11-week wash-out period in between. Patients (men, female, n = 54 + 6) with measurable cardiovascular risk (LDL cholesterol ≥ 120 mg/dl (≥ 3 mmol/l) / triacylglycerides ≥ 135 mg/dl (≥ 1,5 mmol/l)), are involved.

The product range includes sausages (raw, boiled and cooked varieties) and pasta fortified with dietary fibers, fish oil and plant protein, resulting in a reduction of fat and energy content. Eggs, bread, bread rolls, and mushrooms with higher vitamin D content complete the innovative product range. Additionally, participants receive ice cream where sugar is replaced by xylite.

In the control period, the participants receive commercially available foods (sausages (raw, boiled and cooked varieties), pasta, eggs, bread, bread rolls, and mushrooms, ice cream) with traditional nutrient profile.

The products will be offered in neutral packaging and are provided regularly by the study team. All personal (participants, physicians) are blinded.

At the beginning, participants are randomly allocated into the verum or the control/placebo group. After the wash-out phase the interventions will be crossed between the groups and the respective products are consumed also for four weeks. In the run-in phase of the study, all patients are invited to a medical examination to ensure the fulfillment of inclusion criteria.

At the beginning and at the end of each study period baseline parameters (BMI, waist-to-hip ratio, blood pressure, bioelectrical impedance measurement) are assessed, lifestyle questionnaires are filled, and venous blood samples are collected for the determination of cardiovascular risk markers.

Subjects document their normal nutritional habits over seven days in a food frequency protocol (FFP) before start and finish of each period. In addition, patients keep a diary for the documentation of nutrition, medication and adverse effects over both study periods.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 23, 2020
Est. primary completion date March 16, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria:

- females and males

- BMI < 30 kg/m2

- subjects must be able and willing to give written informed consent, and to comply with study procedures

- Participants following a traditional Western diet composed of dairy products, sausage, meat, fast foods, chocolate and snacks, cereals, vegetables, and fruits (PAL: 1.6)

- Precondition: Stable eating habits of at least one years before enrolment

- subjects with moderate elevated LDL cholesterol (= 3 mmol/l) and triacylglyceride concentrations (= 1.5 mmol/l) in plasma, without lipid-lowering medication

- stable dose of antihypertensive medication for > 3 months before study and during the entire study period or without antihypertensive medication

- subjects must have adequate fluency in the German language to complete the questionnaires and understand the nutritional recommendations

Exclusion Criteria:

- subjects with any acute or chronic disease (CVD, tumor, infection, other), gastrointestinal diseases, diabetes mellitus (type I and II), chronic renal disease, diseases of the parathyroid, diseases necessitating regular phlebotomies other chronic diseases which could affect the results of the present study

- use of prescription medicine which could affect results of the study, including systemic glucocorticoids

- intake of lipid-lowering drugs, diabetes medication, hormone replacement therapy

- estimated glomerular filtration (eGFR) rate < 60 ml/min

- weight loss (= 3 kg) or weight gain (= 3 kg) during the last three months before study begin

- pregnancy or lactation

- transfusion of blood in the last three months before blood sample taking

- use of dietary supplements incl. multivitamins, fish oil capsules, minerals, and trace elements (three months before and during the entire study period)

- vegetarians, vegans, food allergies (e.g. milk, nuts etc.)

- dependency on alcohol or drugs

- elite athletes (>10 hours of strenuous physical activity per week)

- simultaneous participation in other clinical studies

- inability (physically or psychologically) to comply with the procedures required by the protocol

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
food range
The food range is comprised of: sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week

Locations

Country Name City State
Germany Friedrich Schiller University Jena Thuringia

Sponsors (1)

Lead Sponsor Collaborator
University of Jena

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary LDL cholesterol cardiovascular risk factor change from baseline after 4 weeks
Secondary blood lipids total cholesterol, HDL cholesterol, triglycerides in mmol/l change from baseline after 4 weeks
Secondary anthropometric data body mass index (kg/m2) change from baseline after 4 weeks
Secondary blood pressure systolic blood pressure (mm Hg) diastolic blood pressure (mmHg) change from baseline after 4 weeks
Secondary lipoprotein a lipoprotein a (mg/l) change from baseline after 4 weeks
Secondary high-sensitive c-reactive protein high-sensitive c-reactive protein (mg/dl) change from baseline after 4 weeks
Secondary homocysteine homocysteine (µmol/l) change from baseline after 4 weeks
Secondary apolipoproteins apolipoproteins A1, B (g/l) change from baseline after 4 weeks
Secondary glucose (fasting) glucose (fasting) (mmol/l) change from baseline after 4 weeks
Secondary insulin (fasting) insulin (fasting) (mU/l) change from baseline after 4 weeks
Secondary hemoglobin A1c (fasting) hemoglobin A1c (fasting) (%) change from baseline after 4 weeks
Secondary malodialdehyde modified LDL cholesterol malodialdehyde modified LDL cholesterol (U/l) change from baseline after 4 weeks
Secondary fatty acid distribution in plasma lipids fatty acid distribution in plasma lipids (%FAME) change from baseline after 4 weeks
Secondary aspartate transaminase (AST) aspartate transaminase (AST) change from baseline after 4 weeks
Secondary alanine transaminase (ALT) alanine transaminase (ALT) change from baseline after 4 weeks
Secondary gamma-glutamyltransferase gamma-glutamyltransferase (gGT) change from baseline after 4 weeks
Secondary Lactate dehydrogenase Lactate dehydrogenase (LDH) change from baseline after 4 weeks
Secondary cholinesterase cholinesterase change from baseline after 4 weeks
Secondary kalium kalium (mmol/l) change from baseline after 4 weeks
Secondary transferrin transferrin (g/l) change from baseline after 4 weeks
Secondary ferritin ferritin (µg/l) change from baseline after 4 weeks
Secondary bioelectrical impedance body water, body fat, lean body mass, extracellular mass (ECM), body cell mass (BCM) change from baseline after 4 weeks
Secondary vitamin A vitamin A (mmol/l) change from baseline after 4 weeks
Secondary vitamin D vitamin A (nmol/l) change from baseline after 4 weeks
Secondary vitamin E vitamin E (µmol/l) change from baseline after 4 weeks
Secondary vitamin B1 vitamin B1 (nmol/l) change from baseline after 4 weeks
Secondary vitamin B6 vitamin B6 (nmol/l) change from baseline after 4 weeks
Secondary vitamin B12 vitamin B12 (pmol/l) change from baseline after 4 weeks
Secondary vitamin B12 status holotranscobalamine (pmol/l) change from baseline after 4 weeks
Secondary creatinine creatinine (mmol/24 h) change from baseline after 4 weeks
Secondary natrium natrium (mmol/24 h) change from baseline after 4 weeks
Secondary magnesium magnesium (mmol/24 h) change from baseline after 4 weeks
Secondary zinc zinc (µmol/24 h) change from baseline after 4 weeks
Secondary albumine albumine (mg/l) (24 h urine) change from baseline after 4 weeks
Secondary uric acid uric acid (mg/dl) (24 h urine) change from baseline after 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04481503 - Transthoracic Echocardiography of Ventricular Function of Parturients in Labor
Terminated NCT04088240 - Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease N/A
Completed NCT03410342 - The Effects of Types of Fruits and Vegetables on Vascular Function N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Recruiting NCT04231838 - Metabolic Syndrome in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Terminated NCT03517111 - The Impact of a Parenting Intervention on Latino Youth Health Behaviors N/A
Completed NCT04562467 - The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk Phase 4
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT04551872 - RESILIENCE: Personalizing Cardiovascular Health N/A
Enrolling by invitation NCT03314818 - Natural History of Carotid Plaque as Determined by 3D Ultrasound N/A
Completed NCT03060811 - Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults N/A
Completed NCT04279704 - Overcoming Obstacles in Epigenetic Analysis of Human Twins
Completed NCT01050205 - The Healthy Lifestyle Project N/A
Completed NCT03570840 - Pediatric Metabolic Syndrome Study
Completed NCT03039023 - Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans N/A
Completed NCT03646175 - Choline Supplementation and Cardiovascular Health N/A

External Links